Vlatković N - Search Results

1

Tissue-specific therapeutic targeting of p53 in cancer: one size does not fit all.

Vlatković N, Crawford K, Rubbi CP, Boyd MT. Vlatković N, et al. Curr Pharm Des. 2011;17(6):618-30. doi: 10.2174/138161211795222568. Curr Pharm Des. 2011. PMID: 21391912 Review.

2

Regulation of p53 and MDM2 activity by MTBP.

Brady M, Vlatkovic N, Boyd MT. Brady M, et al. Among authors: vlatkovic n. Mol Cell Biol. 2005 Jan;25(2):545-53. doi: 10.1128/MCB.25.2.545-553.2005. Mol Cell Biol. 2005. PMID: 15632057 Free PMC article.

3

The nucleolus directly regulates p53 export and degradation.

Boyd MT, Vlatkovic N, Rubbi CP. Boyd MT, et al. Among authors: vlatkovic n. J Cell Biol. 2011 Sep 5;194(5):689-703. doi: 10.1083/jcb.201105143. J Cell Biol. 2011. PMID: 21893597 Free PMC article.

4

p53: a molecular marker for the detection of cancer.

Boyd MT, Vlatkovic N. Boyd MT, et al. Among authors: vlatkovic n. Expert Opin Med Diagn. 2008 Sep;2(9):1013-24. doi: 10.1517/17530059.2.9.1013. Expert Opin Med Diagn. 2008. PMID: 23495923 Free PMC article.

5

Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy.

Vlatković N, Boyd MT, Rubbi CP. Vlatković N, et al. Cell Mol Life Sci. 2014 Mar;71(5):771-91. doi: 10.1007/s00018-013-1361-x. Epub 2013 May 18. Cell Mol Life Sci. 2014. PMID: 23685903 Review.

6

p53 regulation and function in renal cell carcinoma.

Warburton HE, Brady M, Vlatković N, Linehan WM, Parsons K, Boyd MT. Warburton HE, et al. Among authors: vlatkovic n. Cancer Res. 2005 Aug 1;65(15):6498-503. doi: 10.1158/0008-5472.CAN-05-0017. Cancer Res. 2005. PMID: 16061625

7

p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Noon AP, Vlatković N, Polański R, Maguire M, Shawki H, Parsons K, Boyd MT. Noon AP, et al. Among authors: vlatkovic n. Cancer. 2010 Feb 15;116(4):780-90. doi: 10.1002/cncr.24841. Cancer. 2010. PMID: 20052733 Free PMC article. Review.

8

MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism.

Polański R, Warburton HE, Ray-Sinha A, Devling T, Pakula H, Rubbi CP, Vlatković N, Boyd MT. Polański R, et al. Among authors: vlatkovic n. FEBS Lett. 2010 Nov 19;584(22):4695-702. doi: 10.1016/j.febslet.2010.10.049. Epub 2010 Oct 29. FEBS Lett. 2010. PMID: 21034743 Free article.

9

MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.

Polanski R, Maguire M, Nield PC, Jenkins RE, Park BK, Krawczynska K, Devling T, Ray-Sinha A, Rubbi CP, Vlatkovic N, Boyd MT. Polanski R, et al. Among authors: vlatkovic n. Carcinogenesis. 2011 Aug;32(8):1133-42. doi: 10.1093/carcin/bgr070. Epub 2011 Apr 18. Carcinogenesis. 2011. PMID: 21504894

10

Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.

Vlatković N, El-Fert A, Devling T, Ray-Sinha A, Gore DM, Rubbi CP, Dodson A, Jones AS, Helliwell TR, Jones TM, Boyd MT. Vlatković N, et al. Cancer. 2011 Jul 1;117(13):2939-50. doi: 10.1002/cncr.25864. Epub 2011 Jan 10. Cancer. 2011. PMID: 21692053 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page